Sunshine Biopharma Inc. 8-K

What Happened Sunshine Biopharma Inc. (ticker: SBFM) filed a Form 8-K on February 5, 2026, announcing that Dr. Abderrazzak Merzouki resigned from his role as Chief Operating Officer effective immediately. The disclosure was made under Item 5.02 of the Form 8-K. The filing does not state a reason for the resignation or identify a successor.

Key Details

• Filing: Form 8-K under Item 5.02, dated February 5, 2026 (accession 0001683168-26-000789).
• Executive: Dr. Abderrazzak Merzouki resigned as Chief Operating Officer.
• Effective date: Resignation effective immediately on February 5, 2026.
• No successor, reason, or financial/severance details were provided in the filing.

Why It Matters Executive departures can affect a small biotech’s operations, program execution, and investor confidence. This filing provides only the fact of the resignation and no financial or operational impact. Retail investors should monitor Sunshine Biopharma’s future filings and press releases for information about a replacement, any change in operations, or disclosure of related terms.